SOURCES SOUGHT
A -- U.S. Ambulatory Outpatient Trial of Humira� (Adalimumab) in COVID-19
- Notice Date
- 8/26/2020 2:51:24 PM
- Notice Type
- Sources Sought
- NAICS
- 541715
— Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Contracting Office
- W6QK ACC-APG NATICK NATICK MA 01760-5011 USA
- ZIP Code
- 01760-5011
- Solicitation Number
- W911QY-20-S-0023
- Response Due
- 9/3/2020 8:59:00 PM
- Archive Date
- 09/18/2020
- Point of Contact
- Richard Totten, Phone: 3016192446
- E-Mail Address
-
richard.w.totten2.civ@mail.mil
(richard.w.totten2.civ@mail.mil)
- Description
- REQUEST FOR INFORMATION U.S. Ambulatory Outpatient Trial of Humira� (Adalimumab) in COVID-19�� ****Full Announcement Attached to this Posting**** Objective: This is a Request for Information (RFI) for planning purposes only. It is not to be construed as a commitment by the Government nor will the Government pay for the information solicited.� No solicitation document exists or is guaranteed to be issued as a result of this RFI.� The Joint Program Executive Office for Chemical and Biological Defense (Medical Countermeasures Systems) is seeking information on the capabilities and willingness of private entities (academic, non-profit and commercial) in the areas listed below. �
- Web Link
-
SAM.gov Permalink
(https://beta.sam.gov/opp/3b857388102b44e3ac0eddb1c8f4bae6/view)
- Record
- SN05775055-F 20200828/200826230202 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |